β¨ Medicines Consent Notices
13 JANUARY 2005 NEW ZEALAND GAZETTE, No. 1 31
β’ Persons prescribing the medicine must comply with the requirements of the New Zealand Guidelines for the Use of Atypical Anti-Psychotic Drugs (Second Edition September 1998) and the requirements of local hospital and health service protocols for the use of clozapine.
Note: This consent is valid for two years from the date of publication of this notice.
Product: Reyataz
Active Ingredient: Atazanavir sulfate 113.9mg equivalent to 100mg atazanavir
Dosage Form: Capsule
New Zealand Sponsor: Bristol-Myers Squibb (NZ) Company
Manufacturer: Bristol-Myers Squibb Company, Evansville, Indiana, United States of America
Note: This consent is valid for two years from the date of publication of this notice.
Product: Reyataz
Active Ingredient: Atazanavir sulfate 170.84mg equivalent to 150mg atazanavir
Dosage Form: Capsule
New Zealand Sponsor: Bristol-Myers Squibb (NZ) Company
Manufacturer: Bristol-Myers Squibb Company, Evansville, Indiana, United States of America
Note: This consent is valid for two years from the date of publication of this notice.
Product: Reyataz
Active Ingredient: Atazanavir sulfate 227.79mg equivalent to 200mg atazanavir
Dosage Form: Capsule
New Zealand Sponsor: Bristol-Myers Squibb (NZ) Company
Manufacturer: Bristol-Myers Squibb Company, Evansville, Indiana, United States of America
Note: This consent is valid for two years from the date of publication of this notice.
Dated this 6th day of January 2005.
BARRY BORMAN, acting as Deputy Director-General, Public Health, for the period 5 January 2005 to 24 January 2005 (pursuant to delegation given by the Minister of Health on 6 July 2001).
go160
Consent to the Distribution of New Related Products
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new related products set out in the Schedule hereto:
Schedule
Product: Dove Anti-dandruff Shampoo
Active Ingredient: Pyrithione zinc 0.5%w/w
Dosage Form: Shampoo
New Zealand Sponsor: Unilever New Zealand Limited
Manufacturer: Unilever Australasia, North Rocks, New South Wales, Australia
Product: MouthFresh Plus Regular
Active Ingredient: Sodium monofluorophosphate 0.76%w/w
Dosage Form: Toothpaste
New Zealand Sponsor: Global Imports Limited
Manufacturer: Bhavi Tubes and Containers Pvt Limited, Taluka, Kalol, Gandhinagar, Gujarat, India
Product: MouthFresh Plus Spearmint
Active Ingredient: Sodium monofluorophosphate 0.76%w/w
Dosage Form: Toothpaste
New Zealand Sponsor: Global Imports Limited
Manufacturer: Bhavi Tubes and Containers Pvt Limited, Taluka, Kalol, Gandhinagar, Gujarat, India
Product: MouthFresh Plus Tartar Control
Active Ingredient: Sodium monofluorophosphate 0.76%w/w
Dosage Form: Toothpaste
New Zealand Sponsor: Global Imports Limited
Manufacturer: Bhavi Tubes and Containers Pvt Limited, Taluka, Kalol, Gandhinagar, Gujarat, India
Dated this 6th day of January 2005.
BARRY BORMAN, acting as Deputy Director-General, Public Health, for the period 5 January 2005 to 24 January 2005 (pursuant to delegation given by the Minister of Health on 6 July 2001).
go158
Next Page →
Online Sources for this page:
VUW Te Waharoa —
NZ Gazette 2005, No 1
Gazette.govt.nz —
NZ Gazette 2005, No 1
β¨ LLM interpretation of page content
π₯
Provisional Consent to the Distribution of New Medicines
(continued from previous page)
π₯ Health & Social Welfare6 January 2005
Medicines Act, Provisional Consent, Clozapine, Reyataz, Atazanavir sulfate
- BARRY BORMAN, acting as Deputy Director-General, Public Health
π₯ Consent to the Distribution of New Related Products
π₯ Health & Social Welfare6 January 2005
Medicines Act, Consent, Dove Anti-dandruff Shampoo, MouthFresh Plus
- BARRY BORMAN, acting as Deputy Director-General, Public Health